GERN - ジェロン (Geron Corporation) ジェロン

 GERNのチャート


 GERNの企業情報

symbol GERN
会社名 Geron Corp. (ジェロン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェロン(Geron Corporation)はJanssen Biotech Inc. (Janssen)による血液骨髄性悪性腫瘍でファーストインクラスのテロメラーゼ阻害剤、imetelstatを開発する臨床段階のバイオ医薬品会社である。同社は、腫瘍学治療薬の開発に従事している。テロメラーゼのリボ核酸(RNA)鋳型に高親和性で結合し、それによってテロメラーゼ活性を直接阻害するオリゴヌクレオチドであるように、その核酸化学を用いて、イメテスタットを設計した。JanssenはIMbarkと呼ばれる骨髄線維症(MF)の第II相試験、IMergeと呼ばれる骨髄異形成症候群(MDS)の第II / III相試験などの2つの臨床試験でImetelstatの開発に従事する。Imetelstatは、テロメラーゼのRNA鋳型に相補的であり、それと高親和性で結合するように設計され、それによってテロメラーゼ活性を直接阻害するように設計された脂質結合13merオリゴヌクレオチドである。   ジェロンは米国のバイオ医薬品会社で、抗がん剤の開発に焦点に置く。現在製品化に向け、リンパ増殖性疾患、多発性骨髄腫、非小細胞肺がん、乳がん、急性骨髄性白血病のテロメラ―ゼ阻害剤であるイメテルスタットの治験を行う。また、骨髄線維症に対するテロメラ―ゼ阻害剤の予備研究を行う。   Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
本社所在地 149 Commonwealth Drive Suite 2070 Menlo Park CA 94025 USA
代表者氏名 Hoyoung Huh 湖寧
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-473-7700
設立年月日 33178
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 42人
url www.geron.com
nasdaq_url https://www.nasdaq.com/symbol/gern
adr_tso
EBITDA EBITDA(百万ドル) -29.64000
終値(lastsale) 1.835
時価総額(marketcap) 336946417.71
時価総額 時価総額(百万ドル) 306.64880
売上高 売上高(百万ドル) 0.88000
企業価値(EV) 企業価値(EV)(百万ドル) 145.72180
当期純利益 当期純利益(百万ドル) -28.44800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Geron Corporation revenues decreased 26% to $526K. Net loss increased 4% to $14.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 23% to $6.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.09 to -$0.08.

 GERNのテクニカル分析


 GERNのニュース

   Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2020/07/16 12:30:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company. The stock option was granted on July 15, 2020 at an exercise price of $2.04 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock option has a 10-
   How Geron Corporation (GERN) Stock Stands Out in a Strong Industry  2020/06/09 12:40:00 Zacks Investment Research
Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Is Geron (GERN) Outperforming Other Medical Stocks This Year?  2020/06/05 15:30:18 Zacks Investment Research
Is (GERN) Outperforming Other Medical Stocks This Year?
   Top Analyst Upgrades and Downgrades: Amazon, Canopy Growth, CarMax, Chipotle, Geron, Hess, Inogen, Occidental, Snap, Teva, Vail, Zoom Video and More  2020/06/01 12:54:01 24/7 Wall street
   Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates  2020/05/28 22:25:03 Zacks Investment Research
Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress  2020/05/14 13:05:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the Virtual Edition of the European Hematology Association (EHA) Annual Congress to be held online from June 11-14, 2020. The abstracts are available on the EHA website at www.ehaweb.org/c
   Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com  2020/04/20 15:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Primary Myelofibrosis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Myelofibrosis market. A detailed picture of the Primary Myelofibrosis pipeline landscape is provided, which includes the disease overview and Primary Myelofibrosis treatment guidelines. The assess
   MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation and Encourages Investors with Losses to Contact the Firm  2020/03/23 14:40:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $GERN #GERN--MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation.
   The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index  2020/03/10 13:19:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
   MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation and Encourages Investors with Losses to Contact the Firm  2020/03/23 14:40:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $GERN #GERN--MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation.
   The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index  2020/03/10 13:19:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
   GERN INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm  2020/03/09 19:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Geron Corporation (“Geron” or the Company”) (NASDAQ: GERN) and certain of its officers, on behalf of shareholders who purchased Geron securities between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/gern. This class action seeks to recover damage
   Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Geron Corporation  2020/03/05 23:14:00 Business Wire
NEW YORK--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Geron’s business and prospects, resulting in its stock trading at inflated prices.
   Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020  2020/03/05 21:30:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2019 financial results after the market closes on Thursday, March 12, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results and 2020 milestones at 4:30 p.m. ET the same day. Participants may access the conference call live via telephone by diali

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェロン GERN Geron Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)